TY - JOUR
T1 - Nuclear Imaging of Liposomal Drug Delivery Systems: A Critical Review of Radiolabelling Methods and Applications in Nanomedicine
AU - Man, Francis Alexandre Wei Ming
AU - Gawne, Peter James
AU - T. M. de Rosales, Rafael
PY - 2019
Y1 - 2019
N2 - The integration of nuclear imaging with nanomedicine is a powerful tool for efficient development and clinical translation of liposomal drug delivery systems. Furthermore, it may allow highly efficient imaging-guided personalised treatments. In this article, we critically review methods available for radiolabelling liposomes. We discuss the influence that the radiolabelling methods can have on their biodistribution and highlight the often-overlooked possibility of misinterpretation of results due to decomposition in vivo. We stress the need for knowing the biodistribution/pharmacokinetics of both the radiolabelled liposomal components and free radionuclides in order to confidently evaluate the images, as they often share excretion pathways with intact liposomes (e.g. phospholipids, metallic radionuclides) and even show significant tumour uptake by themselves (e.g. some radionuclides). Finally, we describe preclinical and clinical studies using radiolabelled liposomes and discuss their impact in supporting liposomal drug development and clinical translation in several diseases, including personalised nanomedicine approaches.
AB - The integration of nuclear imaging with nanomedicine is a powerful tool for efficient development and clinical translation of liposomal drug delivery systems. Furthermore, it may allow highly efficient imaging-guided personalised treatments. In this article, we critically review methods available for radiolabelling liposomes. We discuss the influence that the radiolabelling methods can have on their biodistribution and highlight the often-overlooked possibility of misinterpretation of results due to decomposition in vivo. We stress the need for knowing the biodistribution/pharmacokinetics of both the radiolabelled liposomal components and free radionuclides in order to confidently evaluate the images, as they often share excretion pathways with intact liposomes (e.g. phospholipids, metallic radionuclides) and even show significant tumour uptake by themselves (e.g. some radionuclides). Finally, we describe preclinical and clinical studies using radiolabelled liposomes and discuss their impact in supporting liposomal drug development and clinical translation in several diseases, including personalised nanomedicine approaches.
KW - Drug delivery
KW - Liposome
KW - Nanomedicine
KW - Nuclear imaging
KW - PET
KW - SPECT
KW - Theranostics
UR - http://www.scopus.com/inward/record.url?scp=85066976656&partnerID=8YFLogxK
U2 - 10.1016/j.addr.2019.05.012
DO - 10.1016/j.addr.2019.05.012
M3 - Review article
SN - 0169-409X
VL - 143
SP - 134
EP - 160
JO - ADVANCED DRUG DELIVERY REVIEWS
JF - ADVANCED DRUG DELIVERY REVIEWS
ER -